Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 1, 2010, Pages 67-77

  Prasad, Vikas ^a   Ambrosini, Valentina ^b   Hommann, Merten ^c   Hoersch, Dieter ^c   Fanti, Stefano ^b   Baum, Richard P ^a  

^a Centre for PET/CT   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c NONE   (Germany)

Author keywords

68Ga DOTA NOC; Molecular imaging; Neuroendocrine tumour; Receptor PET CT; Unknown primary

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; DOTA NOC GALLIUM GA 68; GALLIUM 68; PENTETREOTIDE IN 111; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRONCHOSCOPY; BRONCHUS CARCINOID; COLON; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DISTANT METASTASIS; DRUG DISTRIBUTION; DRUG UPTAKE; DUODENUM; FEMALE; HUMAN; ILEUM; JEJUNUM; LUNG; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PANCREAS; PARAGANGLIOMA; POSITRON EMISSION TOMOGRAPHY; RECTUM; TISSUE DISTRIBUTION;

AGED; FEMALE; HUMANS; MALE; NEOPLASMS, UNKNOWN PRIMARY; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 72949100074     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1205-y     Document Type: Article

References (40)

1. JL Abbruzzese MC Abbruzzese R Lenzi KR Hess MN Raber 1995 Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin J Clin Oncol 13 2094 2103 1:STN:280:DyaK2MzmtlCqtA%3D%3D 7636553
2. T Le Chevalier E Cvitkovic P Caille J Harvey G Contess M Spielmann, et al. 1988 Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients Arch Intern Med 148 2035 2039 10.1001/archinte.148.9.2035 3046543 (Pubitemid 18211044)
3. MS Didolkar N Fanous EG Elias RH Moore 1977 Metastatic carcinomas from occult primary tumors. A study of 254 patients Ann Surg 186 625 630 10.1097/00000658-197711000-00014 1:STN:280:DyaE1c%2FjvFSmtA%3D%3D 921356
4. RJ Steckel AR Kagan 1980 Diagnostic persistence in working up metastatic cancer with an unknown primary site Radiology 134 367 369 1:STN:280: DyaL3c7gt1WntQ%3D%3D 7352215
5. E Briasoulis N Pavlidis 1997 Cancer of unknown primary origin Oncologist 2 142 152 10388044
6. JD Hainsworth FA Greco 1993 Treatment of patients with cancer of an unknown primary site N Engl J Med 329 257 263 10.1056/NEJM199307223290407 1:STN:280:DyaK3szgt1yiuw%3D%3D 8316270 (Pubitemid 23203818)
7. M McCredie M Coates T Churches R Taylor 1991 Cancer incidence in New South Wales, Australia Eur J Cancer 27 928 931 10.1016/0277-5379(91)90149-8 1:STN:280:DyaK38%2FjtVChsQ%3D%3D 1834131
8. C Muir L Weiland 1995 Upper aerodigestive tract cancers Cancer 75 147 153 10.1002/1097-0142(19950101)75:1+<147::AID-CNCR2820751304>3.0.CO;2-U 1:STN:280:DyaK2M%2FpsVWiug%3D%3D 8000993
9. N Pavlidis E Briasoulis J Hainsworth FA Greco 2003 Diagnostic and therapeutic management of cancer of an unknown primary Eur J Cancer 39 1990 2005 10.1016/S0959-8049(03)00547-1 1:STN:280:DC%2BD3svhslyrsA%3D%3D 12957453 (Pubitemid 37297755)
10. MN Raber J Faintuch JL Abbruzzese C Sumrall P Frost 1991 Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin Ann Oncol 2 519 520 1:STN:280:DyaK38%2FgtFKhuw%3D%3D 1911461
11. R Syed JB Bomanji N Nagabhushan S Hughes I Kayani A Groves, et al. 2005 Impact of combined (18)F-FDG PET/CT in head and neck tumours Br J Cancer 92 1046 1050 10.1038/sj.bjc.6602464 1:CAS:528:DC%2BD2MXisVyit7w%3D (Pubitemid 40546667)
12. JL Alberini T Belhocine R Hustinx F Daenen P Rigo 2003 Whole-body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumours (CUP syndrome) Nucl Med Commun 24 1081 1086 10.1097/00006231-200310000-00008 1:STN:280:DC%2BD3svkslKjtg%3D%3D
13. KH Bohuslavizki S Klutmann S Kröger U Sonnemann R Buchert JA Werner, et al. 2000 FDG PET detection of unknown primary tumors J Nucl Med 41 816 822 1:STN:280:DC%2BD3c3mslWqtg%3D%3D 10809197
14. LS Freudenberg M Fischer G Antoch W Jentzen A Gutzeit SJ Rosenbaum, et al. 2005 Dual modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary Med Princ Pract 14 155 160 10.1159/000084632 15863988 (Pubitemid 40663292)
15. A Gutzeit G Antoch H Kühl T Egelhof M Fischer E Hauth, et al. 2005 Unknown primary tumors: detection with dual-modality PET/CT-initial experience Radiology 234 227 234 10.1148/radiol.2341031554 15564390 (Pubitemid 39662772)
16. AC Kole OE Nieweg J Pruim HJ Hoekstra HS Koops JL Roodenburg, et al. 1998 Detection of unknown occult primary tumors using positron emission tomography Cancer 82 1160 1166 10.1002/(SICI)1097-0142(19980315)82:6<1160::AID- CNCR22>3.0.CO;2-3 1:STN:280:DyaK1c7msFWrtQ%3D%3D 9506364 (Pubitemid 28136532)
17. S Adams R Baum T Rink PM Schumm-Dräger KH Usadel G Hör 1998 Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours Eur J Nucl Med 25 79 83 10.1007/s002590050197 1:CAS:528:DyaK2sXnvVGru7o%3D 9396878 (Pubitemid 28107907)
18. V Ambrosini P Tomassetti D Rubello D Campana C Nanni P Castellucci, et al. 2007 Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours Nucl Med Commun 28 473 477 10.1097/MNM.0b013e328182d606 17460538 (Pubitemid 46684197)
19. RP Baum V Prasad M Hommann D Hörsch 2008 Receptor PET/CT imaging of neuroendocrine tumors Recent Results Cancer Res 170 225 242 10.1007/978-3-540- 31203-1-18 1:STN:280:DC%2BD2snos1KgtA%3D%3D 18019630
20. V Ambrosini P Tomassetti P Castellucci D Campana G Montini D Rubello, et al. 2008 Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours Eur J Nucl Med Mol Imaging 35 1431 1438 10.1007/s00259-008-0769-2 1:CAS:528:DC%2BD1cXovFyqur8%3D 18418596
21. KP Zhernosekov DV Filosofov RP Baum P Aschoff H Bihl AA Razbash, et al. 2007 Processing of generator-produced 68Ga for medical application J Nucl Med 48 1741 1748 10.2967/jnumed.107.040378 1:CAS:528:DC%2BD2sXht1GlurnE 17873136 (Pubitemid 47572722)
22. GJ Meyer H Macke J Schuhmacher WH Knapp M Hofmann 2004 68Ga-labelled DOTA-derivatised peptide ligands Eur J Nucl Med Mol Imaging 31 1097 1104 10.1007/s00259-004-1486-0 1:CAS:528:DC%2BD2cXmtFWks7o%3D 15029459
23. KH Neumann JS Nystrom 1982 Metastatic cancer of unknown origin: nonsquamous cell type Semin Oncol 9 427 434 1:STN:280:DyaL3s7pslCltg%3D%3D 7170628
24. JL Abbruzzese MC Abbruzzese KR Hess MN Raber R Lenzi P Frost 1994 Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients J Clin Oncol 12 1272 1280 1:STN:280:DyaK2c3mtVaktQ%3D%3D 8201389
25. E Altman E Cadman 1986 An analysis of 1539 patients with cancer of unknown primary site Cancer 57 120 124 10.1002/1097-0142(19860101)57:1<120:: AID-CNCR2820570124>3.0.CO;2-M 1:STN:280:DyaL28%2FnvFSntw%3D%3D 3940611 (Pubitemid 16212245)
26. CG Moertel RJ Reitemeier AJ Schutt RG Hahn 1972 Treatment of the patient with adenocarcinoma of unknown origin Cancer 30 1469 1472 10.1002/1097- 0142(197212)30:6<1469::AID-CNCR2820300609>3.0.CO;2-T 1:STN:280: DyaE3s%2FmtlWiuw%3D%3D 4641758
27. QS Ringenberg 1985 Tumors of unknown origin Med Pediatr Oncol 13 301 306 10.1002/mpo.2950130510 1:STN:280:DyaL2M3psFOjug%3D%3D 4033541 (Pubitemid 15227892)
28. Jensen RT. Endocrine tumors of the gastrointestinal tract and pancreas. In: Kasper DL, Fauci AS, Longo DL, et al., editors. Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill; 2005
29. V Rufini ML Calcagni RP Baum 2006 Imaging of neuroendocrine tumors Semin Nucl Med 36 228 227 10.1053/j.semnuclmed.2006.03.007 16762613 (Pubitemid 43817847)
30. M Gabriel C Decristoforo D Kendler G Dobrozemsky D Heute C Uprimny, et al. 2007 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT J Nucl Med 48 508 518 10.2967/jnumed.106.035667 1:CAS:528:DC%2BD2sXhtVert7jF (Pubitemid 47571404)
31. D Wild HR Mäcke B Waser JC Reubi M Ginj H Rasch, et al. 2005 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5 Eur J Nucl Med Mol Imaging 32 724 10.1007/s00259-004-1697-4 15551131 (Pubitemid 40897499)
32. D Wild JS Schmitt M Ginj HR Mäcke BF Bernard E Krenning, et al. 2003 DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals Eur J Nucl Med Mol Imaging 30 1338 1347 10.1007/s00259-003-1255-5 1:CAS:528:DC%2BD3sXnslSntL8%3D 12937948 (Pubitemid 37247950)
33. M Hofmann H Maecke R Börner E Weckesser P Schöffski L Oei, et al. 2001 Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data Eur J Nucl Med 28 1751 1757 10.1007/s002590100639 1:CAS:528:DC%2BD3MXosFagurs%3D 11734911
34. G Savelli G Lucignani E Seregni A Marchianò G Serafini G Aliberti, et al. 2004 Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours Nucl Med Commun 25 445 449 10.1097/00006231-200405000-00004 15100502 (Pubitemid 38591104)
35. LJ Hofland SW Lamberts 2003 The pathophysiological consequences of somatostatin receptor internalization and resistance Endocr Rev 24 28 47 10.1210/er.2000-0001 1:CAS:528:DC%2BD3sXhslOgsbw%3D 12588807 (Pubitemid 36223278)
36. G Eisenhofer G Siegert J Kotzerke SR Bornstein K Pacak 2008 Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas Horm Metab Res 40 329 337 10.1055/s-2008-1073156 1:CAS:528:DC%2BD1cXotFyrsbk%3D 18491252 (Pubitemid 351859444)
37. J Mundschenk N Unger S Schulz V Höllt S Schulz R Steinke, et al. 2003 Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy J Clin Endocrinol Metab 88 5150 5157 10.1210/jc.2003-030262 1:CAS:528: DC%2BD3sXptVynsrk%3D 14602742 (Pubitemid 37452710)
38. M Miederer S Seidl A Buck K Scheidhauer HJ Wester M Schwaiger, et al. 2009 Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT Eur J Nucl Med Mol Imaging 36 48 52 10.1007/s00259-008-0944-5 1:CAS:528:DC%2BD1cXhsVGqurzJ 18807033
39. T Zimmer H Scherübl S Faiss U Stölzel EO Riecken B Wiedenmann 2000 Endoscopic ultrasonography of neuroendocrine tumours Digestion 62 Suppl 1 45 50 10.1159/000051855 10940687
40. H Wieder AJ Beer T Poethko G Meisetschlaeger HJ Wester E Rummeny, et al. 2008 PET/CT with Gluc-Lys-([(18)F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions Eur J Nucl Med Mol Imaging 35 264 271 10.1007/s00259-007-0576-1 17912524